Deputies’ Health and Budget Commissions Approve Argentina's Dementia National Plan - One Step Closer to Becoming Law!. ADI welcomes news from Argentina that the government has taken another key step towards the creation of an Alzheimer’s law. On 13 August, A joint meeting of

Do you have a present or future solution for dementia? Be sure to submit an abstract for ADI’s upcoming Global Conference and showcase your solution to international audience of over 1,000 delegates from 100 countries. If your research, innovative solution or activity comes

Join millions who have switched to Grok.

With just one week to go to access our Super Early Bird Rate, we are pleased to shine a light on just some of the key speakers joining us in Lyon, France, from 14-16 April 2026  for the 37th Global Conference of ADI, the world’s longest running international conference on

On 23 September 2025, ADI and the World Health Organization will co-host a special event at the United Nations General Assembly (UNGA). ADI is pleased to offer both in-person and online registration for the upcoming side event, ‘Increasing the Visibility of . Register to attend

Be a Super Early Bird for ADI’s 2026 Global Conference!. We are pleased to share that registration for the ADI Global Conference 2026 in Lyon, France, are now open. However, there are just two weeks remaining to register at the lowest price. Our Super Early Bird offer provides

ADI Chair of the Board Dale Goldhawk, is presenting at AAIC in Toronto, as a panellist for the discussion on “The World Health Organization’s Global Action Plan on Dementia: Where Are We and Where Are We Headed?” . Dale shared the stage with Dr Katrin Seeher, World Health

Today, 25 July 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab (Kisunla) for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology

Thank you to everyone who joined us for our crucial webinar, 'Enhancing Dementia Education Through Global Best Practices', on 22 July. If you missed this important discussion or wish to revisit the valuable insights shared, the full recording is now available on ADI’s YouTube

ADI would like to give a very warm welcome to our new country associations and new board members, as voted on at the ADI Council Meeting on 11 July 2025. We are delighted to welcome new member associations Alzheimer's Ethiopia, St Vincent and the Grenadines Alzheimer’s Disease

There's still time to join us tomorrow, July 22nd, at 1:00 PM (UK Time), for ADI's crucial webinar on dementia education. REGISTER: Discover how fostering knowledge exchange and collaboration can collectively drive progress and elevate care standards for

There is less than one week left to register for ADI’s latest webinar ‘Enhancing Dementia Education Through Global Best Practices’, taking place on 22 July, 1:00 PM (UK Time). Register today: . Join us for this insightful webinar as we bring together

ADI has previously shared the testimonies of people who have been travelling for treatment, based on disparities between regulators. In the coming weeks, we are collecting testimonies of medical practitioners who are providing the latest treatments to people with Alzheimer's

ADI is pleased to announce that registration for the ADI Global Conference 2026 in Lyon, France, opens today!. Learn more and register today: Join us for the 37th Global Conference of Alzheimer's Disease International, 14-16 April 2026, in Lyon, France!

ADI is pleased to share the recent @bmj_latest's article on ‘Improving care for people with dementia through co-creation of action plans in the Western Pacific region’. The article is authored by ADI Board Member @emilyong67 and co-authored by Deputy CEO Chris Lynch, Asia

Today, July 7th, the Scottish Medicines Consortium (SMC) has upheld its decision not to recommend lecanemab for early stage Alzheimer's disease for use within the Scottish National Health Service. This outcome means people living with Alzheimer's and their families in Scotland

The National Institute for Health and Care Excellence has concluded that the benefits from two treatments for early Alzheimer's Disease, #donanemab and #lecanemab, remain too small to justify the additional cost. The committee concluded that if these treatments were

ADI has launched the latest campaign toolkits for the upcoming World Alzheimer’s Month global campaign this September. Access a free selection of social media cards, posters, and infographics, as well as useful advice on how to raise awareness about dementia, key statistics, and